Sarah H. Koenigsberg

ORCID: 0000-0002-0334-5552 · 2 papers in corpus

peer-review 2020

Author response for "Estimating the effect of elagolix treatment for endometriosis on post‐menopausal bone outcomes: a model bridging registrational phase III trials to an older real‐world population"

·doi:10.1002/jbm4.10401/v2/response1

article 2020

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population

JBMR plus ·doi:10.1002/jbm4.10401

ABSTRACT Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed …